QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
|
|
|
(State or other jurisdiction of Incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
|
|
|
Large accelerated filer
|
☐
|
|
☑
|
|
Non-accelerated filer
|
☐
|
Smaller reporting company
|
|
|
Emerging growth company
|
|
Page No.
|
|||
PART I—FINANCIAL INFORMATION
|
|||
ITEM 1
|
Financial Statements (Unaudited)
|
||
5
|
|||
6
|
|||
7
|
|||
8
|
|||
9
|
|||
Consolidated Statements of Changes in Stockholders’ Equity for the six months ended June 30, 2024 and 2023 | 10 |
||
|
|||
11
|
|||
ITEM 2
|
33
|
||
ITEM 3
|
45 |
||
ITEM 4
|
46 |
||
PART II—OTHER INFORMATION
|
|||
ITEM 1
|
47 |
||
ITEM 1A
|
47 |
||
ITEM 2
|
47 |
||
ITEM 3
|
47 | ||
ITEM 4
|
47 |
||
ITEM 5
|
47 | ||
ITEM 6
|
48 | ||
49 |
● |
declining sales of tobacco products, and expected continuing decline of sales in the tobacco industry overall;
|
● |
our dependence on a small number of third-party suppliers and producers;
|
● |
the possibility that we will be unable to identify or contract with new suppliers or producers in the event of a supply or product disruption, as well as
other supply chain concerns, including delays in product shipments and increases in freight cost;
|
● |
the possibility that our licenses to use certain brands or trademarks will be terminated, challenged or restricted;
|
● |
failure to maintain consumer brand recognition and loyalty of our customers;
|
● |
our reliance on relationships with several large retailers and national chains for distribution of our products;
|
● |
intense competition and our ability to compete effectively;
|
● |
competition from illicit sources and the damage caused by illicit products to our brand equity;
|
●
|
contamination of our tobacco supply or products;
|
● |
uncertainty and continued evolution of the markets for our products;
|
● |
complications with the design or implementation of our new enterprise resource planning system could adversely impact our business and operations;
|
● |
substantial and increasing regulation and changes in U.S. Food and Drug Administration (“FDA”) enforcement priorities;
|
● |
regulation or marketing denials of our products by the FDA, which has broad regulatory powers;
|
● |
many of our products contain nicotine, which is considered to be a highly addictive substance;
|
● |
requirement to maintain compliance with master settlement agreement escrow account;
|
● |
possible significant increases in federal, state and local municipal tobacco- and nicotine-related taxes;
|
● |
our products are marketed pursuant to a policy of FDA enforcement priorities which could change, and our products could become subject to increased
regulatory burdens by the FDA;
|
|
●
|
uncertainty related to the PMTA application process;
|
● |
our products are subject to developing and unpredictable regulation, such as court actions that impact obligations;
|
● |
increase in state and local regulation of our products has been proposed or enacted;
|
● |
increase in tax of our products could adversely affect our business;
|
● |
sensitivity of end-customers to increased sales taxes and economic conditions, including as a result of inflation and other declines in purchasing power;
|
● |
possible increasing international control and regulation;
|
● |
failure to comply with environmental, health and safety regulations;
|
● |
imposition of significant tariffs on imports into the U.S.;
|
● |
the scientific community’s lack of information regarding the long-term health effects of certain substances contained in some of our products;
|
● |
significant product liability litigation;
|
● |
our amount of indebtedness;
|
● |
the terms of our indebtedness, which may restrict our current and future operations;
|
●
|
our ability to establish and maintain effective internal controls over financial reporting;
|
● |
identification of material weaknesses in our internal control over financial reporting, which, if not remediated appropriately or timely, could result in
loss of investor confidence and adversely impact our stock price;
|
● |
our certificate of incorporation and bylaws, as well as Delaware law and certain regulations, could discourage or prohibit acquisition bids or merger
proposals, which may adversely affect the market price of our common stock;
|
● |
our certificate of incorporation limits the ownership of our common stock by individuals and entities that are Restricted Investors. These restrictions may
affect the liquidity of our common stock and may result in Restricted Investors (as defined in our Certificate of Incorporation) being required to sell or redeem their shares at a loss or relinquish their voting, dividend and distribution
rights;
|
● |
future sales of our common stock in the public market could reduce our stock price, and any additional capital raised by us through the sale of equity or
convertible securities may dilute your ownership in us;
|
● |
we may issue preferred stock whose terms could adversely affect the voting power or value of our common stock;
|
● |
our business may be damaged by events outside of our suppliers’ control, such as the impact of epidemics (e.g., coronavirus), political upheavals, or natural
disasters;
|
● |
adverse impact of climate change;
|
● |
our reliance on information technology;
|
● |
cybersecurity and privacy breaches, which have increased in part due to artificial intelligence;
|
● |
failure to manage our growth;
|
● |
failure to successfully integrate our acquisitions or otherwise be unable to benefit from pursuing acquisitions;
|
● |
fluctuations in our results;
|
● |
exchange rate fluctuations;
|
● |
adverse U.S. and global economic conditions;
|
● |
departure of key management personnel or our inability to attract and retain talent;
|
● |
infringement on or misappropriation of our intellectual property;
|
● |
third-party claims that we infringe on their intellectual property; and
|
● |
failure to meet expectations relating to environmental, social and governance factors.
|
(unaudited)
|
||||||||
June 30, | December 31, | |||||||
ASSETS
|
2024
|
2023
|
||||||
Current assets:
|
||||||||
Cash
|
$
|
|
$
|
|
||||
Accounts receivable, net of allowances of $
|
|
|
||||||
Inventories, net
|
|
|
||||||
Other current assets
|
|
|
||||||
Total current assets
|
|
|
||||||
Property, plant, and equipment, net
|
|
|
||||||
Deferred income taxes
|
|
|
||||||
Right of use assets
|
|
|
||||||
Deferred financing costs, net
|
|
|
||||||
Goodwill
|
|
|
||||||
Other intangible assets, net
|
|
|
||||||
Master Settlement Agreement (MSA) escrow deposits
|
|
|
||||||
Other assets
|
|
|
||||||
Total assets
|
$
|
|
$
|
|
||||
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
Current liabilities:
|
||||||||
Accounts payable
|
$
|
|
$
|
|
||||
Accrued liabilities
|
|
|
||||||
Current portion of long-term debt
|
||||||||
Total current liabilities
|
|
|
||||||
Notes payable and long-term debt
|
|
|
||||||
Lease liabilities
|
|
|
||||||
Total liabilities
|
$ |
|
$ |
|
||||
Commitments and contingencies
|
||||||||
Stockholders’ equity:
|
||||||||
Preferred stock, $
|
|
|
||||||
Common stock, voting, $
|
|
|
||||||
Common stock, nonvoting, $
|
|
|
||||||
Additional paid-in capital
|
|
|
||||||
Cost of repurchased common stock (
|
(
|
)
|
(
|
)
|
||||
Accumulated other comprehensive loss
|
(
|
)
|
(
|
)
|
||||
Accumulated earnings
|
|
|
||||||
Non-controlling interest
|
|
|
||||||
Total stockholders’ equity
|
|
|
||||||
Total liabilities and stockholders’ equity
|
$
|
|
$
|
|
Three Months Ended
June 30,
|
Six
Months Ended
June 30,
|
|||||||||||||||
2024
|
2023
|
2024
|
2023
|
|||||||||||||
Net sales (1)
|
$
|
|
$
|
|
$ | $ | ||||||||||
Cost of sales
|
|
|
||||||||||||||
Gross profit
|
|
|
||||||||||||||
Selling, general, and administrative expenses
|
|
|
||||||||||||||
Other operating income |
( |
) | ( |
) | ||||||||||||
Operating income
|
|
|
||||||||||||||
Interest expense, net
|
|
|
||||||||||||||
Investment loss
|
|
|
||||||||||||||
Gain on extinguishment of debt
|
( |
) | ( |
) | ||||||||||||
Income before income taxes
|
|
|
||||||||||||||
Income tax expense
|
|
|
||||||||||||||
Consolidated net income
|
|
|
||||||||||||||
Net (loss) income attributable to non-controlling interest
|
(
|
)
|
(
|
)
|
( |
) | ||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$ |
$ |
||||||||||
Basic income per common share:
|
||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$ |
$ |
||||||||||
Diluted income per common share:
|
||||||||||||||||
Net income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
$ |
$ |
||||||||||
Weighted average common shares outstanding:
|
||||||||||||||||
Basic
|
|
|
||||||||||||||
Diluted
|
|
|
(1) | |
Three Months Ended
June 30
|
||||||||
2024
|
2023
|
|||||||
Consolidated net income
|
$
|
|
$
|
|
||||
Other comprehensive income (loss), net of tax
|
||||||||
Unrealized loss on MSA investments, net of tax of $
|
(
|
)
|
(
|
)
|
||||
Foreign currency translation, net of tax of $
|
(
|
)
|
(
|
)
|
||||
Unrealized gain (loss) on derivative instruments, net of tax of $
|
|
(
|
)
|
|||||
Unrealized loss on captive investments, net of tax of $
|
( |
) | ||||||
(
|
)
|
(
|
)
|
|||||
Consolidated comprehensive income
|
|
|
||||||
Comprehensive loss attributable to non-controlling interest
|
(
|
)
|
(
|
)
|
||||
Comprehensive income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
Six
Months Ended
June 30,
|
||||||||
2024
|
2023
|
|||||||
Consolidated net income
|
$
|
|
$
|
|
||||
Other comprehensive income (loss), net of tax
|
||||||||
Unrealized (loss) gain on MSA investments,
net of tax of $
|
(
|
)
|
|
|||||
Foreign currency translation, net of tax
of $
|
(
|
)
|
(
|
)
|
||||
Unrealized loss on derivative instruments,
net of tax of $
|
(
|
)
|
(
|
)
|
||||
(
|
)
|
(
|
)
|
|||||
Consolidated comprehensive income
|
|
|
||||||
Comprehensive income (loss) attributable to non-controlling interest
|
|
(
|
)
|
|||||
Comprehensive income attributable to Turning Point Brands, Inc.
|
$
|
|
$
|
|
Six
Months Ended
June 30,
|
||||||||
2024
|
2023
|
|||||||
Cash flows from operating activities:
|
||||||||
Consolidated net income
|
$
|
|
$
|
|
||||
Adjustments to reconcile net income to net cash provided by operating activities:
|
||||||||
Gain on extinguishment of debt
|
|
(
|
)
|
|||||
Loss on sale of property, plant, and equipment
|
|
|
||||||
Loss on MSA investments
|
||||||||
Depreciation and other amortization expense
|
|
|
||||||
Amortization of other intangible assets
|
|
|
||||||
Amortization of deferred financing costs
|
|
|
||||||
Deferred income tax expense
|
|
|
||||||
Stock compensation expense
|
|
|
||||||
Noncash lease income
|
(
|
)
|
(
|
)
|
||||
Loss on investments
|
|
|
||||||
Changes in operating assets and liabilities:
|
||||||||
Accounts receivable
|
(
|
)
|
|
|||||
Inventories
|
(
|
)
|
(
|
)
|
||||
Other current assets
|
|
|
||||||
Other assets
|
(
|
)
|
(
|
)
|
||||
Accounts payable
|
|
|
||||||
Accrued liabilities and other
|
(
|
)
|
(
|
)
|
||||
Net cash provided by operating activities
|
$
|
|
$
|
|
||||
Cash flows from investing activities:
|
||||||||
Capital expenditures
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Purchases of investments
|
( |
) | ||||||
Proceeds from sale of investments
|
||||||||
Purchases of non-marketable equity investments
|
( |
) | ||||||
Proceeds on the sale of property, plant and equipment
|
|
|
||||||
Restricted cash, MSA escrow deposits
|
||||||||
Net cash used in investing activities
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Cash flows from financing activities:
|
||||||||
Convertible Senior Notes repurchased
|
$ | $ | ( |
) | ||||
Proceeds from call options
|
||||||||
Payment of financing costs
|
( |
) | ||||||
Payment of dividends
|
(
|
)
|
(
|
)
|
||||
Exercise of options
|
|
|
||||||
Redemption of options
|
( |
) | ( |
) | ||||
Redemption of restricted stock units
|
( |
) | ||||||
Redemption of performance based restricted stock units
|
( |
) | ( |
) | ||||
Common stock repurchased
|
(
|
)
|
|
|||||
Net cash used in financing activities
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Net increase (decrease) in cash
|
$
|
|
$
|
(
|
)
|
|||
Effect of foreign currency translation on cash
|
$
|
(
|
)
|
$
|
(
|
)
|
||
Cash, beginning of period:
|
||||||||
Unrestricted
|
$
|
|
$
|
|
||||
Restricted
|
|
|
||||||
Total cash at beginning of period
|
$
|
|
$
|
|
||||
Cash, end of period:
|
||||||||
Unrestricted
|
$
|
|
$
|
|
||||
Restricted
|
|
|
||||||
Total cash at end of period
|
$
|
|
$
|
|
||||
Supplemental schedule of noncash investing activities:
|
||||||||
Accrued capital expenditures
|
$
|
|
$
|
|
||||
Supplemental schedule of noncash financing activities:
|
||||||||
Dividends declared not paid
|
$
|
|
$
|
|
Cost of | Accumulated | |||||||||||||||||||||||||||||||
Common | Additional |
Repurchased
|
Other |
Non-
|
||||||||||||||||||||||||||||
Voting | Stock, | Paid-In |
Common
|
Comprehensive
|
Accumulated | Controlling | ||||||||||||||||||||||||||
Shares
|
Voting
|
Capital
|
Stock
|
Income (Loss)
|
Earnings
|
Interest
|
Total
|
|||||||||||||||||||||||||
Beginning balance April 1, 2024
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $
|
–
|
|
|
|
(
|
)
|
|
|
(
|
)
|
||||||||||||||||||||||
Unrealized gain on derivative instruments, net of tax of $
|
– | |||||||||||||||||||||||||||||||
Foreign currency translation, net of tax of $
|
–
|
|
|
|
(
|
)
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||
Unrealized loss on investments, net of tax of $
|
– | ( |
) | ( |
) | |||||||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Redemption of options |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Cost of repurchased common stock
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Issuance of performance based restricted stock units
|
||||||||||||||||||||||||||||||||
Issuance of restricted stock units
|
||||||||||||||||||||||||||||||||
Redemption of restricted stock units
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Dividends
|
–
|
|
|
|
|
(
|
)
|
|
(
|
)
|
||||||||||||||||||||||
Net income
|
–
|
|
|
|
|
|
(
|
)
|
|
|||||||||||||||||||||||
Ending balance June 30, 2024
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Beginning balance April 1, 2023
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $
|
–
|
|
|
|
(
|
)
|
|
(
|
)
|
|||||||||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $
|
– |
( |
) | ( |
) | |||||||||||||||||||||||||||
Foreign currency translation, net of tax of $
|
– | ( |
) | ( |
) | ( |
) | |||||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|||||||||||||||||||||||||
Redemption of options |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Issuance of performance restricted stock units
|
||||||||||||||||||||||||||||||||
Redemption of performance restricted stock units
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Settlement of call options, net of tax of $
|
– | |||||||||||||||||||||||||||||||
Dividends
|
–
|
|
|
|
|
(
|
)
|
(
|
)
|
|||||||||||||||||||||||
Net income
|
–
|
|
|
|
|
|
( |
) |
|
|||||||||||||||||||||||
Ending balance June 30, 2023
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
Accumulated | ||||||||||||||||||||||||||||||||
Common | Additional |
Cost of
|
Other |
Non-
|
||||||||||||||||||||||||||||
Voting | Stock, | Paid-In |
Repurchased
|
Comprehensive
|
Accumulated | Controlling | ||||||||||||||||||||||||||
Shares
|
Voting
|
Capital
|
Common Stock
|
Income (Loss)
|
Earnings
|
Interest
|
Total
|
|||||||||||||||||||||||||
Beginning balance January 1, 2024
|
|
$
|
|
$
|
|
$
|
(
|
)
|
$
|
(
|
)
|
$
|
|
$
|
|
$
|
|
|||||||||||||||
Unrealized loss on MSA investments, net of tax of $
|
–
|
|
|
|
(
|
)
|
|
|
(
|
)
|
||||||||||||||||||||||
Unrealized loss on derivative instruments, net of tax of $
|
– | ( |
) | ( |
) | |||||||||||||||||||||||||||
Foreign currency translation, net of tax of $
|
–
|
|
|
|
|
|
(
|
)
|
(
|
)
|
||||||||||||||||||||||
Stock compensation expense
|
–
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Exercise of options
|
|
|
|
|
|
|
|
|
||||||||||||||||||||||||
Redemption of options |
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Cost of repurchased common stock
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Issuance of performance based restricted stock units
|
||||||||||||||||||||||||||||||||
Redemption of performance based restricted stock units
|
( |
) | ( |
) | ( |
) | ||||||||||||||||||||||||||
Issuance of restricted stock units
|